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E. Garcia-Flores, A. Martinez-Campos and R. Farias
Osier Clinic, Monterrey, Mexico
The objective of this study was to determine
whether the associated morbidity and mortality
of adrenal medulla autologous transplantation
into the striatum (open transcortical procedure)
justifies this as a safe and effective treatment for
Parkinson’s Disease (PD).
METHODS
The 4 year postoperative status was evaluated
in 17 patients with PD who were recipients of
adrenal medulla autologous transplants between
August, 1987 and August, 1988. The results were
compared with those obtained at the two year
follow-up published in 1990/1/.
Two patients were lost to follow-up and two
additional patients died of pneumonia (aside
from the 3 deaths we reported in 1990).
The parameters evaluated included:
c)
d)
a) The Unified Parkinson’s Disease Rating
Scale (UPDRS), including: the modified
Hoehn/Yahr scale, Schwab and England
assessment score, mentation, activities of
daily living (ADL), and motor examination;
b) Neuropsychological evaluation (12 pa-
tients);
Neurophysiological evaluation (10 patients);
Pre- and postoperative diabetes mellitus and
endocrine evaluation.
Data forms were collected at baseline, and at
24 and 48 months postoperative periods. All
medical complications were registered. Ten of
the seventeen surviving patients had MRI of the
brain postoperatively.
RESULTS
1. Two patients (9%) showed long lasting
improvement. However, we identified some
characteristics that put them out of the mean
group of the illness"
a) PD started at early age; 24 (B.B.) and 41
years (B.C.);
b) One of the patients was exposed to
DDT (B.C.);
c) Neither of the two had received Lev-
odopa on a regular basis.
2. A second group (23%) showed a disability
score quite similar to the preoperative level.
This related to a less aggressive course of PD
that we considered brought the clinical course to
a "plateau".
3. The third group (68%) showed a progressive
aggravation of the symptoms, and was the de-
positary of most of the complications. There
were three operative deaths related to the surgi-
cal procedure, two within 30 days after surgery,
and one in the first 3 months. These data showed
an overall operative mortality of 12%. Two addi-
tional deaths occurred 18 and 36 months after
the operations were performed, both of them
due to pneumonia.
4. This group of operated patients presented
signs of long-term deleterious effects on the re-
gulation of the hypothalamic-hypophyseal ad-
renocortical axis, for example, decreased cortisol
level and a two-fold incidence of diabetes
mellitus after surgery (17%). We related this to
a reduction in the tolerance of stress after uni-
lateral adrenalectomy, particularly in patients
over 55/2/.
5. This group also showed signs of progressive
ageing as shown by Schwab and England scores.
Radiological or NMRI changes of the brain, as
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well as EEG changes, were present in ageing
relatively young adults. Finally, a progressive
decline of I.Q., particularly short-term memory,
was seen.
These conclusions are similar to the ones re-
ported by our group two years ago, and are in
agreement with the recent report by the United
Parkinson Foundation Neurotransplantation
Registry/3/.
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TABLE
Base line 2 years 4 years
No. of patients 24 20 17
Female 9 7 7
Male 15 13 10
UPDRS
Mentation
Group
Group II
Group III
6.5 6.5 (0) 6.5 (0)
7.25 7.50 (-.25) 7.75 (-.5)
6.50 8.00 (-.1.5) 8.75 (-.2.25)
ADL
Group 32.5 21.25 (+ 11.3) 20.5 (+ 12)
Group II 23.5 22.5 (+ 1.5) 23.15 (-0.35)
Group II 53 62.8 (-9.8) 75.6 (-12.6)
Motor
Group 46.5 30 (+ 16.5) 20 (+26.5)
Group II 39.0 38.7 (+0.3) 42.5 (-3.5)
Group III 40 48 (-8) 60.5 (-20.5)
Hoehn/Yahr
Group I 3.5 2.1 (+ 1.4) 2.7 (+0.8)
Group II 3.0 2.75 (+0.25) 3.50 (-0.5)
Group III 3.5 3.8 (-0.3) 4.5 (-1.0)
Schwab/England
Group 40 80 (+40) 70 +30)
Group II 50 52.5 (+2.5) 50.5 (+0.5)
Group III 55 45 (-10) 30 (-25)
Group 78 72.5 (-5.5) 70.5 (-7.5)
Group II 102.3 94.3 (-8) 92.3 (-10)
Group III 78.5 70.5 (-8) 60.6 (-13.9)
UPDRS denotes Unified Parkinson’s Disease Rating
Scale, and ADL activities of daily living scale. Values in
parentheses represent changes in the mean score as
compared with the base-line scores. Negative signs indicate
decline from base-line. Mentation UPDRS ranges from 0
(normal) to 16 (very abnormal) and positive signs indicate
improvement, ADL ranges from 0 (normal) to 70 (very
abnormal). Motor ranges from 0 (normal) to 68 (very
abnormal. H/Y stages range from 0.5 (least disabled) to 5.0
(most disabled). Schwab/England scale ranges from 100
percent (no disability) to 0 percent (extreme disability).